None listed
Conditions
Interventions
Drug : According to the current atrial fibrillation guidelines, the target number of single-center, prospective study-blind randomization targets was calculated at a ratio of 1:1 between the simultane
Sponsors
Inha University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Patients with non-membrane persistent atrial fibrillation over the age of 19 and converted to sinus rhythm using atrial fibrillation high-frequency electrode catheter resection, electrical sinus rhythm conversion, or antiarrhythmic drugs in our hospital ? Patients with hypertension and dyslipidemia who require medication ? Patients who agree with the purpose of this study
Exclusion criteria
Exclusion criteria: ? Atrial fibrillation associated with structural heart disease, which is affected by severe cardiac malformation or hemodynamic factors ? severe renal dysfunction ? Patients with a history of atrial fibrillation high frequency electrode catheter resection or labyrinth surgery ? Patients with significant mitral valve stenosis (moderate or higher) ? a patient diagnosed with hypertrophic cardiomyopathy ? a serious co-morbid condition of manifestation ? a patient expected to have a survival period of less than one year ? Patients deemed unfit to participate in clinical trials by other researchers' judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of patients included in the RCT using normal sinus rhythm maintenance, Intention to treat analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| -Adjust blood pressure (average self-blood pressure monitoring figures, average 24-hour active blood pressure monitoring figures) - LDL cholesterol control (compared LDL-C assessment with baseline LDL-C at 6 and 12 months follow-up) - Assessment of cerebral infarction incidence, hospitalization rate, cardiovascular incidence rate, mortality rate, and quality of life (SF-36);- Hypotension (drug-induced orthostatic hypotension-related symptoms) - Target organ damage (serum creatinine change, liver level, serum electrolyte change, renal function change, left ventricular hypertrophy, etc.) occurs - During the study period, 95% confidence intervals will be presented for all abnormalities collected during the survey period and important potential risk (rhabdomyolysis, severe hypotension, edema, fetal toxicity, liver enzymes and dysfunction) in the safety assessment group, and a table of the expression status of each type of abnormal case will be prepared | — |
Countries
Korea, Republic of
Contacts
Public ContactHyo Bin Shin
Inha University Hospital
Outcome results
None listed